Clover Biopharmaceuticals Ltd
02197
Company Profile
Business description
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
Contact
No. 758 West Nanjing Road
Room 1901
Jing’an District
Shanghai
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
257
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Market concerns over governance and AI fears have left shares trading well below the fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.80 | 20.00 | 0.22% |
| CAC 40 | 8,326.62 | 73.96 | 0.90% |
| DAX 40 | 25,118.27 | 220.82 | 0.89% |
| Dow JONES (US) | 52,487.41 | 139.02 | 0.27% |
| FTSE 100 | 10,472.45 | 16.59 | -0.16% |
| HKSE | 24,103.09 | 72.91 | 0.30% |
| NASDAQ | 26,206.89 | 336.24 | 1.30% |
| Nikkei 225 | 69,205.30 | 1,461.45 | 2.16% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,543.64 | 60.93 | 0.81% |
| S&P/ASX 200 | 8,791.80 | 24.00 | 0.27% |
| SSE Composite Index | 4,045.17 | 8.58 | 0.21% |